Dear Reader :
This month’s newsletter, co-developed by the IPA and Citeline, highlights all the big talking points at the BIO International Convention in San Diego and the return of momentum in the clinical trials arena.
We tell you why Amgen’s CEO had some tough words on the Inflation Reduction Act, labelling it the ‘Innovation Reduction Act’ at BIO and also spotlight key trial trends now that the pandemic-related turmoil has abated.
There’s also a fascinating piece on advances in minimally invasive bioelectronics for mental health.
Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA
|